sales@fortunebusinessinsights.com">
炎症性肠病治疗市场Size, Share & COVID-19 Impact Analysis, By Disease Indication (Ulcerative Colitis and Crohn’s Disease), By Route of Administration (Oral and Injectables), By Drug Class (IL Inhibitors, TNF Inhibitors, Anti-integrin, JAK Inhibitors, Corticosteroids, ASA Drugs, and Others), By Distribution Channel (Hospital Pharmacy and Retail Pharmacy & Other), and Regional Forecast, 2022-2029
区域:全球|格式:PDF |报告ID:FBI106704
分享